AI health tech company—developer of the world’s largest dataset and biobank for infection in acute care—will study the health states of suspected septic patients in hospitals
CHICAGO, July 12, 2023 /PRNewswire/ — Prenosis, Inc., an artificial intelligence company enabling precision medicine in acute care, announced today that it has been awarded two Phase 2 SBIR grants totaling $4.8M in funding by the National Institute of General Medical Sciences (NIGMS), a division of the National Institute of Health (NIH). The grants will study the use of Prenosis’s Immunix™ Artificial Intelligence platform for acute immune states. Prenosis has built a collection of artificial intelligence algorithms, broad clinical data, deep biological data, and biobanked samples of patients suspected of sepsis, in addition to detailed information about their treatment regime. The goal is to better understand how patients’ health states rapidly evolve in acute care environments.
The outcomes of these studies could usher in a new era of predictive diagnostics, clinical decision support tools, improved clinical trials, and precision medicine drugs for sepsis.
To help fulfill the promise of AI in acute care, Prenosis’ platform leverages machine learning trained on a combination of broad clinical data and deep biological data to improve outcomes. In acute care settings, Prenosis’ Immunix™ platform promises to identify and treat patients’ individual biology, enabling better health outcomes.